Correction: Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test (Clinical Gastroenterology and Hepatology (2016) 14(10) (1445–1451.e8) (S154235651630204X) (10.1016/j.cgh.2016.05.017));Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 10, 2016, Pages 1445-1451.e8

  Meester, Reinier G S ^a   Zauber, Ann G ^b   Doubeni, Chyke A ^c   Jensen, Christopher D ^d   Quinn, Virginia P ^e   Helfand, Mark ^f   Dominitz, Jason A ^g,h   Levin, Theodore R ^d   Corley, Douglas A ^d   Lansdorp Vogelaar, Iris ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d DIVISION OF RESEARCH   (United States)

^e KAISER PERMANENTE   (United States)

^f VETERANS AFFAIRS PORTLAND HEALTH CARE SYSTEM   (United States)

^g VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Colorectal Neoplasms; Occult Blood; Screening and Early Detection; Time Factors

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER TEST; COLONOSCOPY; COLORECTAL CANCER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FECAL IMMUNOCHEMICAL TEST; FECES ANALYSIS; FOLLOW UP; HUMAN; IMMUNOASSAY ANALYZER; IMMUNOCHEMISTRY; OCCULT BLOOD TEST; SENSITIVITY ANALYSIS; STOOL DNA TEST; UNITED STATES; COHORT ANALYSIS; COLORECTAL NEOPLASMS; COMPUTER SIMULATION; DIAGNOSTIC TEST; FEMALE; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; MORTALITY; PROCEDURES; SURVIVAL ANALYSIS; TIME FACTOR; UTILIZATION;

AGED; COHORT STUDIES; COLONOSCOPY; COLORECTAL NEOPLASMS; COMPUTER SIMULATION; DIAGNOSTIC TESTS, ROUTINE; FEMALE; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; SURVIVAL ANALYSIS; TIME FACTORS; UNITED STATES;

EID: 84991031559     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2018.02.023     Document Type: Erratum

References (67)

1. 1 Siegel, R., Ma, J., Zou, Z., et al. Cancer statistics, 2014. CA Cancer J Clin 64 (2014), 9–29.
2. 2 Hardcastle, J.D., Chamberlain, J.O., Robinson, M.H., et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348 (1996), 1472–1477.
3. 3 Kronborg, O., Fenger, C., Olsen, J., et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348 (1996), 1467–1471.
4. 4 Mandel, J.S., Church, T.R., Ederer, F., et al. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 91 (1999), 434–437.
5. 5 Partin, M.R., Burgess, D.J., Burgess, J.F. Jr., et al. Organizational predictors of colonoscopy follow-up for positive fecal occult blood test results: an observational study. Cancer Epidemiol Biomarkers Prev 24 (2015), 422–434.
6. 6 Chubak, J., Garcia, M.P., Burnett-Hartman, A.N., et al. Time to colonoscopy after positive fecal blood test in four U.S. health care systems. Cancer Epidemiol Biomarkers Prev 25 (2016), 344–350.
7. 7 Peterson K, Carson S, Humphrey L, et al. Patients with positive screening fecal occult blood tests: evidence brief on the relationship between time delay to colonoscopy and colorectal cancer outcomes. 2013. Available at: http://www.hsrd.research.va.gov/publications/esp/fecaloccult.pdf.
8. 8 Gellad, Z.F., Almirall, D., Provenzale, D., et al. Time from positive screening fecal occult blood test to colonoscopy and risk of neoplasia. Dig Dis Sci 54 (2009), 2497–2502.
9. 9 Cancer Intervention and Surveillance Modeling Network (CISNET). Colorectal cancer model profiles. National Cancer Institute, 2013. Available from: http://cisnet.cancer.gov/colorectal/profiles.html. Accessed January 1, 2013.
10. 10 Zauber, A.G., Lansdorp-Vogelaar, I., Knudsen, A.B., et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 149 (2008), 659–669.
11. 11 Jorgensen, O.D., Kronborg, O., Fenger, C., A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 50 (2002), 29–32.
12. 12 Winawer, S.J., Zauber, A.G., O'Brien, M.J., et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps: the National Polyp Study Workgroup. N Engl J Med 328 (1993), 901–906.
13. 13 Chiu, H.M., Chen, S.L., Yen, A.M., et al. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. Cancer 121 (2015), 3221–3229.
14. 14 Parente, F., Marino, B., DeVecchi, N., et al. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer. Br J Surg 96 (2009), 533–540.
15. 15 Parente, F., Vailati, C., Boemo, C., et al. Improved 5-year survival of patients with immunochemical faecal blood test-screen-detected colorectal cancer versus non-screening cancers in northern Italy. Dig Liver Dis 47 (2015), 68–72.
16. 16 Weinstein, M.C., Siegel, J.E., Gold, M.R., et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276 (1996), 1253–1258.
17. 17 Levin, B., Lieberman, D.A., McFarland, B., et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 58 (2008), 130–160.
18. 18 Lieberman, D.A., Rex, D.K., Winawer, S.J., et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 143 (2012), 844–857.
19. 19 Meester, R.G., Doubeni, C.A., Lansdorp-Vogelaar, I., et al. Variation in adenoma detection rate and the lifetime benefits and cost of colorectal cancer screening: a microsimulation model. JAMA 313 (2015), 2349–2358.
20. 20 Rex, D.K., Johnson, D.A., Anderson, J.C., et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 104 (2009), 739–750.
21. 21 Kuntz, K.M., Lansdorp-Vogelaar, I., Rutter, C.M., et al. A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med Decis Making 31 (2011), 530–539.
22. 22 Brenner, H., Altenhofen, L., Katalinic, A., et al. Sojourn time of preclinical colorectal cancer by sex and age: estimates from the German national screening colonoscopy database. Am J Epidemiol 174 (2011), 1140–1146.
23. 23 Wattacheril, J., Kramer, J.R., Richardson, P., et al. Lagtimes in diagnosis and treatment of colorectal cancer: determinants and association with cancer stage and survival. Aliment Pharmacol Ther 28 (2008), 1166–1174.
24. 24 Ramos, M., Esteva, M., Cabeza, E., et al. Lack of association between diagnostic and therapeutic delay and stage of colorectal cancer. Eur J Cancer 44 (2008), 510–521.
25. 25 Korsgaard, M., Pedersen, L., Sorensen, H.T., et al. Delay of treatment is associated with advanced stage of rectal cancer but not of colon cancer. Cancer Detect Prev 30 (2006), 341–346.
26. 26 Murchie, P., Raja, E.A., Brewster, D.H., et al. Time from first presentation in primary care to treatment of symptomatic colorectal cancer: effect on disease stage and survival. Br J Cancer 111 (2014), 461–469.
27. 27 Lansdorp-Vogelaar, I., Kuntz, K.M., Knudsen, A.B., et al. Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med 153 (2010), 368–377.
28. 28 Knudsen, A.B., Lansdorp-Vogelaar, I., Rutter, C.M., et al. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst 102 (2010), 1238–1252.
29. 29 Wu, G.H., Wang, Y.M., Yen, A.M., et al. Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries. BMC Cancer, 6, 2006, 136.
30. 30 Mandel, J.S., Church, T.R., Bond, J.H., et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 343 (2000), 1603–1607.
31. 31 Quintero, E., Castells, A., Bujanda, L., et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 366 (2012), 697–706.
32. 32 Lansdorp-Vogelaar, I., Gulati, R., Mariotto, A.B., et al. Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med 161 (2014), 104–112.
33. 33 Rex, D.K., Ahnen, D.J., Baron, J.A., et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 107 (2012), 1315–1329 quiz 4, 30.
34. 1 Centers for Disease Control and Prevention 2010. Available at: http://www.cdc.gov/nchs/products/life_tables.htm. Accessed October 28, 2013.
35. 2 Rutter, C.M., Johnson, E.A., Feuer, E.J., et al. Secular trends in colon and rectal cancer relative survival. J Natl Cancer Inst 105 (2013), 1806–1813.
36. 3 Surveillance Epidemiology and End Results Program 2014. Available at: National Cancer Institute at http://seer.cancer.gov/seerstat/. Accessed January 1, 2015.
37. 4 Williams, A.R., Balasooriya, B.A., Day, D.W., Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut 23 (1982), 835–842.
38. 5 Vatn, M.H., Stalsberg, H., The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer 49 (1982), 819–825.
39. 6 Rickert, R.R., Auerbach, O., Garfinkel, L., et al. Adenomatous lesions of the large bowel: an autopsy survey. Cancer 43 (1979), 1847–1857.
40. 7 Johannsen, L.G., Momsen, O., Jacobsen, N.O., Polyps of the large intestine in Aarhus, Denmark: an autopsy study. Scand J Gastroenterol 24 (1989), 799–806.
41. 8 Jass, J.R., Young, P.J., Robinson, E.M., Predictors of presence, multiplicity, size and dysplasia of colorectal adenomas: a necropsy study in New Zealand. Gut 33 (1992), 1508–1514.
42. 9 Blatt, L.J., Polyps of the colon and rectum: incidence and distribution. Dis Colon Rectum 4 (1961), 277–282.
43. 10 Arminski, T.C., McLean, D.W., Incidence and distribution of adenomatous polyps of the colon and rectum based on 1,000 autopsy examinations. Dis Colon Rectum 7 (1964), 249–261.
44. 11 Bombi, J.A., Polyps of the colon in Barcelona, Spain: an autopsy study. Cancer 61 (1988), 1472–1476.
45. 12 Chapman, I., Adenomatous polypi of large intestine: incidence and distribution. Ann Surg 157 (1963), 223–226.
46. 13 Clark, J.C., Collan, Y., Eide, T.J., et al. Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. Int J Cancer 36 (1985), 179–186.
47. 14 Hardcastle, J.D., Chamberlain, J.O., Robinson, M.H., et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348 (1996), 1472–1477.
48. 15 Jorgensen, O.D., Kronborg, O., Fenger, C., A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 50 (2002), 29–32.
49. 16 Mandel, J.S., Church, T.R., Ederer, F., et al. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 91 (1999), 434–437.
50. 17 Lansdorp-Vogelaar, I., van Ballegooijen, M., Boer, R., et al. A novel hypothesis on the sensitivity of the fecal occult blood test: results of a joint analysis of 3 randomized controlled trials. Cancer 115 (2009), 2410–2419.
51. 18 Efron, B., Tibshirani, R., An introduction to the bootstrap. 1993, CRC Press LLC, Boca Raton, FL.
52. 19 Imperiale, T.F., Ransohoff, D.F., Itzkowitz, S.H., et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370 (2014), 1287–1297.
53. 20 van Rijn, J.C., Reitsma, J.B., Stoker, J., et al. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 101 (2006), 343–350.
54. 21 Meester, R.G., Doubeni, C.A., Lansdorp-Vogelaar, I., et al. Variation in adenoma detection rate and the lifetime benefits and cost of colorectal cancer screening: a microsimulation model. JAMA 313 (2015), 2349–2358.
55. 22 Warren, J.L., Klabunde, C.N., Mariotto, A.B., et al. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med 150 (2009), 849–857 W152.
56. 23 Gatto, N.M., Frucht, H., Sundararajan, V., et al. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst 95 (2003), 230–236.
57. 24 Atkin, W.S., Edwards, R., Kralj-Hans, I., et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375 (2010), 1624–1633.
58. 25 Burch, J.A., Soares-Weiser, K., St John, D.J., et al. Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. J Med Screen 14 (2007), 132–137.
59. 26 Lee, J.K., Liles, E.G., Bent, S., et al. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med, 160, 2014, 171.
60. 27 Gohel, T.D., Burke, C.A., Lankaala, P., et al. Polypectomy rate: a surrogate for adenoma detection rate varies by colon segment, gender, and endoscopist. Clin Gastroenterol Hepatol 12 (2014), 1137–1142.
61. 28 Williams, J.E., Holub, J.L., Faigel, D.O., Polypectomy rate is a valid quality measure for colonoscopy: results from a national endoscopy database. Gastrointest Endosc 75 (2012), 576–582.
62. 29 Imperiale, T.F., Wagner, D.R., Lin, C.Y., et al. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 343 (2000), 169–174.
63. 30 Lieberman, D.A., Weiss, D.G., Bond, J.H., et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer: Veterans Affairs Cooperative Study Group 380. N Engl J Med 343 (2000), 162–168.
64. 31 Zauber, A.G., Knudsen, A.B., Rutter, C.M., et al. Cost-effectiveness of CT colonography to screen for colorectal cancer. 2007, Agency for Healthcare Research and Quality, Rockville, MD.
65. 32 Leffler, D.A., Kheraj, R., Garud, S., et al. The incidence and cost of unexpected hospital use after scheduled outpatient endoscopy. Arch Intern Med 170 (2010), 1752–1757.
66. 33 Yabroff, K.R., Lamont, E.B., Mariotto, A., et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 100 (2008), 630–641.
67. 34 American Joint Committee on Cancer. AJCC cancer staging manual. 5th ed., 1997, Lippincott-Raven Publishers, Philadelphia.